"label","text","name","uuid:ID","description","id","instanceType"
"","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","OBJ1","c8e415ad-b443-400d-806c-05677d20f61b","Main objective","Objective_1","Objective"
"","To document the safety profile of the xanomeline TTS.","OBJ2","2cf1276d-f621-42cf-88b3-7f08abba79b3","Safety","Objective_2","Objective"
"","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","OBJ3","4e66e9f6-3c9a-45d0-a052-146501d2b8ec","Behaviour","Objective_3","Objective"
